GILEAD SCIENCES CMV TRIAL DATA MAKE FOR BALMY VIEW BY THE STREET IN JANUARY
Executive Summary
Gilead Sciences started off the new year by gaining 3-1/2 points (36.8%) in January as the Foster City, Calif.-based company announced positive study results for its lead product, Vistide (cidofovir), for treatment of cytomegalovirus retinitis in AIDS patients
You may also be interested in...
EU Notified Body Association Takes Steps To Allay EC’s Virtual Audit Fears
The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.
New UK Biosimilars Pathway Suffers Setback
The UK’s implementation of a new national licensing framework for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as the cause of an indefinite delay in the consultation process.
Hikma Suspends Roll-Out Of Advair Rival
Hikma has temporarily stopped the roll-out of its rival to Advair Diskus in the US after it filed an amendment to its ANDA over packaging controls.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: